Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
| no clinical added value |
" In view of : - the efficacy and safety data versus placebo, - the absence of direct comparative data versus other anti-ANF agents, particularly infliximab, the Transparency Committee considers that SIMPONI (golimumab) does not provide any improvement in actual benefit (IAB V, non-existent) in the treatment of moderately to severely active UC which is resistant to conventional therapies." |
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
kBg9sfaPg0gJv8CQ
Listen
